Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine in High Risk Pediatric Leukemia Post Allogeneic Transplant
NCT02264873Phase 1Completed
- Sponsor
- University of Florida
- Start
- Oct 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of decitabine in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Florida. Primary endpoint: Maximum Tolerated Dose at 3 months. Started Oct 2014; status: completed.
02
Drugs
decitabine
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02264873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264873.